Labsystems Diagnostics teams up with Shimadzu Corporation
National, Date - Labsystems Diagnostics, Helsinki, an enterprise of
Trivitron Healthcare, healthcare multinational headquartered in Chennai,
entered into a an agreement with Shimadzu Corporation, Japan, leader in
analytical instruments, for clinical diagnostics in the area of Newborn
Screening (NBS). NBS is a preventive pediatric screening service to
assess the occurrence of genetic metabolic disorders. These disorders
could lead to permanent neurological, cognitive, and physical damage in
the child. When these disorders are detected early enough they can be
easily treated.
The companies will cooperate to leverage Labsystems reagent
technology leadership and Shimadzu world class instrumentation to enable
their global customer base to detect more disorders in newborns, more
rapidly and with greater accuracy.
Labsystems furthermore announces the availability of its new
generation NeoMass AAAC assay fully validated on Shimadzu mass
spectrometry platforms. NeoMass AACC enables investigators for the first
time to detect the entire spectrum of Urea Cycle Metabolic Disorders (UCMD)
in newborns. This assay detects the broadest range of non derivatized
analytes available today.
Fabrizio RADICE, Global Sales & Mktg Director, Labsystems
Diagnostics, Helsinki commented "Our alliance with Shimadzu will enable
us to develop unparalleled integrated solutions for NBS, of which
NeoMass AACC is only the start. Co-development on this level allows us
to leverage the impressive technology leadership of Shimadzu
instrumentation to provide sensitivity to new disorders, and to provide
faster throughput and greater accuracy, which is the key to
investigators success in detecting disorders in babies. We believe our
cooperation will have an impact on the suffering caused by these severe,
yet eminently preventable diseases".
Dr. Geraldine Carrard, CEO - Labsystems Diagnostics Oy added, "The
deliberations and discussions have paved the way of a trusted and solid
partnership. Shimadzu Trivitron Labsystems Diagnostics combination will
be an innovative driving force to reckon within the Newborn Screening."
Shuzo Maruyama, General Manager, Analytical & Measuring Instruments
Division Shimadzu Corporation said 'The agreement between Shimadzu
Corporation and LabSystems Diagnostics will help to change the way in
new born screening programs can be better, expanding the screening
capability with detailed analytics and actionable data creating a new
solution for faster, confident diagnosis. Shimadzu is always exploring
ways to find a solution that meets a real need and makes a difference to
overcome real world challenges. We believe this collaboration with
LabSystems Diagnostics will help make smart decisions quicker and will
make clinical laboratories more efficient and effective in new born
screening'. |